Tamsulosin and Solifenacin in the treatment of Benign Prostatic Hyperplasia in combination with overactive bladder | Wang | Pakistan Journal of Medical Sciences
 
میز اداری صندلی مدیریتی صندلی اداری تبلیغات کلیکی میز تلویزیون پاراگلایدر آگهی رایگان محسن چاوشی مسیح و آرش آهنگ جدید لباس زیر شورت زنانه خرید اینترنتی وبلاگدهی گن لاغری

Tamsulosin and Solifenacin in the treatment of Benign Prostatic Hyperplasia in combination with overactive bladder

Hui Wang, Yanhua Chang, Hui Liang

Abstract


Objective: To analyze the clinical effect of tamsulosin and Solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder and its safety. Another objective was to investigate the clinical effect and safety of mega dose of tamsulosin in the treatment of benign prostatic hyperplasia in combination with overactive bladder.

Methods: One hundred and twenty-four patients who were admitted to the Dept. of Urology at Binzhou People’s Hospital, , China  with confirmed benign prostatic hyperplasia (BPH) with overactive bladder were randomly divided into two groups. Sixty-two patients in the control group were treated with tamsulosin, while sixty-two patients in the observation group were treated with tamsulosin in combination with solifenacin. The treatment of both groups lasted for 12 weeks. The effect and adverse reaction were compared between the two groups.

Results: The international prostate symptom score (IPSS), quality of life (QOL), and overactive bladder symptom score (OABSS), Qmax, pulmonary vascular resistance (PVR), daytime urination frequency, urgent urination frequency, urge urinary incontinence frequency and night urinary frequency of both groups improved after treatment, and the difference had statistical significance (P<0.05). The differences of the observation indexes (except PVR) in the observation group before and after treatment was significantly different with those of the control group (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, but the difference had no statistical significance (X2=2.843, P>0.05).

Conclusion: Treating benign prostatic hyperplasia in combination with overactive bladder with tamsulosin in combination with solifenacin is more effective than tamsulosin, without significantly increasing adverse reactions. Thus the therapy is worth clinical promotion.

doi: https://doi.org/10.12669/pjms.334.12757

How to cite this:Wang H, Chang Y, Liang H. Tamsulosin and Solifenacin in the treatment of Benign Prostatic Hyperplasia in combination with overactive bladder. Pak J Med Sci. 2017;33(4):988-992.   doi: https://doi.org/10.12669/pjms.334.12757

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Full Text: PDF

Refbacks

  • There are currently no refbacks.

Comments on this article

View all comments


kalsob-01_1303_01